FIDAXOMICIN
PSEUDOMEMBRANOUS COLITIS AGENTS · CLOSTRIDIOIDES DIFFICILE INFECTION
SANDOZ
Drug class
Pseudomembranous Colitis Agents
"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class. Read more about Pseudomembranous Colitis Agents
55 drugs in this class 45 manufacturers
Drugs in Pseudomembranous Colitis Agents
Filter & compare in the drug finder →
Opens the drug finder with Pseudomembranous Colitis Agents preselected. Add indication or manufacturer filters there.
"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class.
It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine.
These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well as metronidazole—work by inhibiting bacterial cell-wall synthesis, RNA polymerase transcription, or DNA replication locally within the gastrointestinal tract.
Consequently, their primary therapeutic application is the treatment and clinical resolution of acute or recurrent *C.
difficile*–associated diarrhea and pseudomembranous colitis.
-
drugs.com
"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well ...
-
mayoclinic.org
It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine
-
nih.gov
It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine
-
nih.gov
These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well as metronidazole—work by inhibiting bacterial cell-wall synthesis, RNA polymerase transcription, or DNA replication locally within the gastrointestinal tract Consequently, their primary therapeutic application is the treatment and clinical resolution of acute or recurrent *C. difficile*–associated diarrhea and pseudomembranous colitis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.